Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)

被引：0
|
作者：
Moore, M. [1 ]
Hall, R. [2 ]
Mcloughlin, E. [2 ]
Melson, J. [1 ]
Horton, B. [3 ]
Mills, A. [4 ]
Gentzler, R. [2 ]
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[2] Univ Virginia, Div Hematol Oncol, Charlottesville, VA USA
[3] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, AL USA
[4] Univ Virginia, Pathol, Charlottesville, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
IDO1; NSCLC; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-75
引用
收藏
页码：S738 / S738
页数：1
相关论文
共 50 条
  • [31] Immune checkpoint inhibitors' (ICI) efficacy according to PD-L1 expression for advanced or metastatic NSCLC: Systematic review and meta-analysis.
    Maciel, Glauber
    Carlos, Paula
    Murad Junior, Munir
    Araujo, Vania Eloisa
    Guerra, Augusto
    Acurcio, Francisco Assis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] PD-L1 protein expression as a predictor of response to immune checkpoint inhibitor (ICI) in hepatocellular carcinoma (HCC): A meta-analysis
    Wang, Z.
    Xu, Y.
    Gong, F.
    Gao, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S694 - S694
  • [33] ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
    Zou, Wei
    Yaung, Stephanie J.
    Fuhlbrueck, Frederike
    Ballinger, Marcus
    Peters, Eric
    Palma, John F.
    Shames, David S.
    Gandara, David
    Jiang, Yuqiu
    Patil, Namrata S.
    JCO PRECISION ONCOLOGY, 2021, 5 : 827 - 838
  • [34] A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
    Wang, Yuanyuan
    Gu, Tingxuan
    Tian, Xueli
    Li, Wenwen
    Zhao, Ran
    Yang, Wenqian
    Gao, Quanli
    Li, Tiepeng
    Shim, Jung-Hyun
    Zhang, Chengjuan
    Liu, Kangdong
    Lee, Mee-Hyun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [35] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
  • [36] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
  • [37] Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1
    Hacking, Sean
    Chavarria, Hector
    Jin, Cao
    Perry, Alexander
    Nasim, Mansoor
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)
  • [38] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [39] Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
    Chen, Chian-Wei
    Lin, Chien-Yu
    Tsai, Jeng-Shiuan
    Lin, Chia-Yin
    Chang, Chao-Chun
    Yen, Yi-Ting
    Tseng, Yau-Lin
    Su, Po-Lan
    Lin, Chien-Chung
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381
12345